Skip to main content
. 2022 Mar 3;12:3549. doi: 10.1038/s41598-022-07597-3

Figure 4.

Figure 4

Comparison of Genscript sVNT with the Wantai SARS-CoV-2 NAbs ELISA (A) and the Euroimmun NeutraLISA (B). Data points are color-coded according to their positivity in PRNT (blue: PRNT negative, orange: PRNT positive). Gray dashed line in (A): Wantai nABs ELISA manufacturer-recommended cutoff. Shaded areas in (A,B): equivocal areas; in-house for GenScript sVNT and manufacturer-recommended for Euroimmun NeutraLISA. (A) As the Wantai Nabs ELISA is marketed for qualitative use, the manufacturer does not recommend a conversion of the raw data into binding inhibition and hence no correlation to the sVNT was calculated. Due to the competitive nature of the assay, the signal is inversely correlated with the amount of neutralizing antibodies in a sample. Identical sample sets were used in (A,B) (N = 111).